Skip to content
Boost Up Blog – Lifestyle
Author:
BioAge Labs, Inc.
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
November 5, 2026
BioAge Labs to Present at Upcoming Investor Conferences
September 25, 2026
Diabetic Macular Edema Trial: BioAge Doses First Patient in Phase 2 Study
September 8, 2026
BioAge Labs to Present at Upcoming Investor Conferences
September 2, 2026
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 5, 2026
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
June 16, 2026
BioAge Labs to Present at Upcoming Investor Conferences
May 22, 2026